Literature DB >> 15760586

Outcomes and disease activity measures for assessing treatments in the idiopathic inflammatory myopathies.

Chester V Oddis1.   

Abstract

The assessment and treatment of patients with idiopathic inflammatory myopathy has taken a major step forward over the past few years. Through the efforts of multi-disciplinary international groups of experts interested in the management of patients with myositis, initiatives have led to the development of a core set of outcome measures critical to their assessment. Similarly, the lack of consensus on several issues of clinical trial design has been addressed resulting in the development of a definition of clinical improvement for adult and juvenile patients with inflammatory myopathy using the core set outcomes. The final step in the puzzle of well-designed therapeutic trials in myositis is the determination of consensus guidelines to conduct such trials in adult and pediatric populations of myositis patients.

Entities:  

Mesh:

Year:  2005        PMID: 15760586     DOI: 10.1007/s11926-005-0059-y

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  18 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  A functional index in myositis.

Authors:  A Josefson; E Romanus; J Carlsson
Journal:  J Rheumatol       Date:  1996-08       Impact factor: 4.666

3.  Association of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index with measures of disease activity and health status in patients with systemic lupus erythematosus.

Authors:  T Stoll; G Stucki; J Malik; S Pyke; D A Isenberg
Journal:  J Rheumatol       Date:  1997-02       Impact factor: 4.666

4.  Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study Group.

Authors:  D J Lovell; C B Lindsley; R M Rennebohm; S H Ballinger; S L Bowyer; E H Giannini; J E Hicks; J E Levinson; R Mier; L M Pachman; M H Passo; M D Perez; A M Reed; K N Schikler; M Smith; L S Zemel; L G Rider
Journal:  Arthritis Rheum       Date:  1999-10

Review 5.  Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies.

Authors:  F W Miller; L G Rider; Y L Chung; R Cooper; K Danko; V Farewell; I Lundberg; C Morrison; L Oakley; I Oakley; C Pilkington; J Vencovsky; K Vincent; D L Scott; D A Isenberg
Journal:  Rheumatology (Oxford)       Date:  2001-11       Impact factor: 7.580

Review 6.  Defining Clinical Improvement in Adult and Juvenile Myositis.

Authors:  Lisa G Rider; Edward H Giannini; Michael Harris-Love; Galen Joe; David Isenberg; Clarissa Pilkington; Peter A Lachenbruch; Frederick W Miller
Journal:  J Rheumatol       Date:  2003-03       Impact factor: 4.666

Review 7.  Clinical assessment in adult onset idiopathic inflammatory myopathy.

Authors:  S M Sultan
Journal:  Curr Opin Rheumatol       Date:  2004-11       Impact factor: 5.006

Review 8.  International consensus on preliminary definitions of improvement in adult and juvenile myositis.

Authors:  Lisa G Rider; Edward H Giannini; Hermine I Brunner; Nicola Ruperto; Laura James-Newton; Ann M Reed; Peter A Lachenbruch; Frederick W Miller
Journal:  Arthritis Rheum       Date:  2004-07

9.  Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Juvenile Dermatomyositis Disease Activity Collaborative Study Group.

Authors:  L G Rider; B M Feldman; M D Perez; R M Rennebohm; C B Lindsley; L S Zemel; C A Wallace; S H Ballinger; S L Bowyer; A M Reed; M H Passo; I M Katona; F W Miller; P A Lachenbruch
Journal:  Arthritis Rheum       Date:  1997-11

10.  Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children.

Authors:  L M Pachman; J R Hayford; A Chung; C A Daugherty; M A Pallansch; C W Fink; H L Gewanter; R Jerath; B A Lang; J Sinacore; I S Szer; A R Dyer; M C Hochberg
Journal:  J Rheumatol       Date:  1998-06       Impact factor: 4.666

View more
  1 in total

Review 1.  A systematic review of studies that aim to determine which outcomes to measure in clinical trials in children.

Authors:  Ian Sinha; Leanne Jones; Rosalind L Smyth; Paula R Williamson
Journal:  PLoS Med       Date:  2008-04-29       Impact factor: 11.069

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.